Thrombosis and Hemostasis Biomarkers Market – By Product, By Test Location, By Test Type, By Application, By End Use – Global Forecast, 2024 – 2032

Thrombosis and Hemostasis Biomarkers Market Size

The global thrombosis and hemostasis biomarkers market size was valued at USD 5.2 billion in 2023 and is estimated to grow at a CAGR of over 5.8% from 2024 to 2032. The market is experiencing robust growth, driven by rising incidences of cardiovascular and clotting disorders, advances in biomarker research, and a growing emphasis on personalized medicine.
 

For instance, according to the World Health Organization (WHO), cardiovascular diseases alone contribute to nearly one-third of all global deaths, taking an estimated 17.9 million lives each year, underscoring an urgent need for precise diagnostic tools that support timely intervention.
 

Moreover, breakthroughs in molecular diagnostics and proteomics enable the identification of thrombosis- and hemostasis-specific biomarkers, empowering more accurate risk assessment and individualized treatment strategies. Furthermore, pharmaceutical companies are increasingly focused on biomarker-driven anticoagulants and procoagulant therapies with fewer adverse effects, enhancing patient adherence and clinical outcomes. These innovations are critical in thrombosis management, where biomarker-based insights improve detection, risk assessment, and treatment efficacy in conditions like deep vein thrombosis, pulmonary embolism, and bleeding disorders, supporting more precise, effective patient care.
 

The market encompasses diagnostic and prognostic biomarkers used to assess blood clot formation and bleeding disorders, aiding in disease management for conditions like deep vein thrombosis, stroke, and hemophilia.
 

Thrombosis and Hemostasis Biomarkers Market Trends

Technological advancements in biomarker testing are significantly propelling growth in the market. Cutting-edge technologies, such as high-sensitivity immunoassays, next-generation sequencing (NGS), and digital PCR, are enabling the highly accurate detection of thrombosis- and hemostasis-related biomarkers, providing deeper insights into disease mechanisms and patient-specific risk factors. Enhanced analytical platforms, such as multiplex assays and automated coagulation analyzers, streamline workflows in clinical laboratories, improving both diagnostic speed and reliability.
 

Moreover, advances in point-of-care testing devices allow for rapid, on-site biomarker assessment, which is vital for emergency scenarios like stroke or pulmonary embolism. Additionally, non-invasive biomarker testing methods are becoming more prevalent, enabling continuous patient monitoring with minimal discomfort. Collectively, these innovations are driving improved patient outcomes, personalized therapies, and more efficient healthcare delivery.
 

Thrombosis and Hemostasis Biomarkers Market Analysis

Based on product, the market is segmented into analyzers and reagents & consumables. The reagents & consumables segment dominated the market with USD 3.3 billion in 2023.
 

• The reagents and consumables segment in the market plays a pivotal role in diagnostic and research applications. This segment includes a range of products such as assay kits, chemicals, buffers, and other reagents essential for accurate testing and analysis of hemostatic and thrombotic biomarkers.
   
• Moreover, high demand is driven by the need for precise and rapid detection methods for disorders like deep vein thrombosis, pulmonary embolism, and other clotting abnormalities.
   
• Furthermore, these products also support assays that detect biomarkers such as fibrinogen, D-dimer, and prothrombin time, which are vital for monitoring clotting disorders and anticoagulant therapy.

Based on test location, the market is divided into clinical laboratory tests and point-of-care tests. The clinical laboratory tests segment accounted for significant market share of 64.1% in 2023.
 

• The clinical laboratory tests segment in the thrombosis and hemostasis biomarkers market is fundamental for diagnosing and managing clotting disorders and thrombotic conditions. This segment includes specialized tests such as D-dimer testing, prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet function tests, which are essential for identifying abnormalities in coagulation pathways.
   
• Furthermore, these tests help assess bleeding risks, monitor anticoagulation therapy, and evaluate the efficiency of thrombosis prevention methods. Driven by an increase in cardiovascular diseases, obesity, and aging populations, the demand for accurate and timely diagnostic tests is growing significantly.
   

Based on test type, the market is segmented into D-dimer, anti-thrombin III, plasminogen, soluble fibrin, factor VIII, post-thrombin (PT), activated partial thromboplastin time (APTT) test, and other test types. The D-dimer segment dominated the market with USD 1.4 billion in 2023.
 

• The D-dimer test segment is a critical component within the thrombosis and hemostasis biomarkers market, widely utilized for diagnosing thrombotic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE). This test detects D-dimer levels, a protein fragment produced when a blood clot dissolves, helping to assess clotting abnormalities and monitor conditions like disseminated intravascular coagulation (DIC).
   
• As an initial screening tool, D-dimer testing is valued for its high sensitivity and ability to exclude thrombotic events when results are normal, reducing the need for more invasive diagnostic methods.
   

Based on application, the market is divided into deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and other applications. The deep vein thrombosis (DVT) segment dominated the market with USD 1.9 billion in 2023.
 

• The deep vein thrombosis (DVT) application segment in the thrombosis and hemostasis biomarkers market addresses the critical need for timely and accurate diagnosis of blood clots in deep veins, primarily in the legs. DVT poses significant health risks, as clots can travel to the lungs, causing pulmonary embolism (PE), a life-threatening complication.
   
• Biomarker testing for DVT involves assays for D-dimer, fibrinogen, and coagulation factors that provide rapid insights into clotting abnormalities.
   
• Thus, the segment's growth is largely driven by the rising incidence of risk factors such as sedentary lifestyles, obesity, and an aging population, which increase DVT occurrences.
   

Based on end use, the market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. The hospitals and clinics segment dominated the market with USD 2.7 billion in 2023 and expected to reach 4.4 billion within the forecast period.
 

• The hospitals and clinics segment is a vital component of the thrombosis and hemostasis biomarkers market, primarily due to the high demand for reliable diagnostic testing in acute care settings.
   
• These institutions rely on a range of biomarker tests, including D-dimer, fibrinogen, and coagulation factor assays, to swiftly diagnose and manage clotting disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
   
• Given the critical nature of these conditions, hospitals prioritize high-throughput and accurate testing methods to support effective treatment decisions, often utilizing automated coagulation analyzers and point-of-care testing (POCT) options.

The U.S. thrombosis and hemostasis biomarkers market are expected to grow at 5.8% CAGR, to reach USD 3 billion by the end of 2032.
 

• The U.S. market is well established and poised for growth, driven by high rates of cardiovascular disease. For instance, according to the American Heart Association, cardiovascular disease (CVD) remains the leading cause of death in the U.S., accounting for 928,741 deaths in 2020.
   
• Significant R&D investment and widespread adoption of precision medicine enhance the demand for biomarkers in thrombosis and hemostasis. The presence of major biotechnology and pharmaceutical companies accelerates advancements in biomarker discovery and commercialization, with a focus on early detection and tailored therapies.
   
• Additionally, rising healthcare expenditures and a supportive regulatory environment foster the rapid integration of novel diagnostic tools in clinical settings. The increasing use of point-of-care testing devices and non-invasive diagnostics further streamlines patient care and fuels market expansion.
   

The Germany thrombosis and hemostasis biomarkers market is experiencing robust growth in Europe.  
 

• The market in Germany is expanding due to its robust medical infrastructure, high rates of cardiovascular disease, and government-supported research initiatives. The German healthcare system prioritizes precision medicine and innovative diagnostic solutions, fueling demand for advanced biomarker technologies.
   
• Furthermore, collaborations between research institutions and biotechnology firms drive development, while patient awareness of genetic and proteomic testing fosters adoption.
   

The Asia Pacific thrombosis and hemostasis biomarkers market is witnessing substantial growth of 6.1% during the analysis period.
 

• The Chinese market is experiencing rapid growth due to an increasing incidence of lifestyle-related diseases and significant investment in healthcare modernization. China’s expansion of healthcare infrastructure, especially in urban centers, supports the adoption of advanced diagnostics.
   
• Furthermore, as awareness grows, non-invasive biomarker testing and point-of-care solutions are increasingly favored, improving access to diagnostic services and creating a strong market path.
   

Brazil is experiencing robust growth in Latin America thrombosis and hemostasis biomarkers market.
 

• In Brazil, the market is developing steadily, with growth driven by rising rates of cardiovascular disease, a shift toward private healthcare, and increased government healthcare spending. However, market expansion faces challenges due to regional healthcare disparities and limited access in rural areas.
   
• Investments in hospital and diagnostic infrastructure, particularly in urban regions, are enhancing access to biomarker-based testing. Additionally, collaborations with international healthcare firms are introducing advanced diagnostic tools to the market.
   

The Saudi Arabia thrombosis and hemostasis biomarkers market is witnessing substantial growth during the analysis period.
 

• Saudi Arabia represents a growing market due to rising cardiovascular disease rates, a high prevalence of diabetes, and government-led healthcare reforms. Investments aligned with the Saudi Vision 2030 plan focus on improving healthcare infrastructure and increasing diagnostic capabilities.
   
• An aging population and increasing awareness of preventative healthcare drive demand for early diagnostic solutions, including biomarker testing for thrombosis and hemostasis.
   

Thrombosis and Hemostasis Biomarkers Market Share

The market is dominated by leading biotechnology and pharmaceutical firms, driven by high demand for accurate diagnostics and precision treatments in cardiovascular care. Major players leverage robust biomarker portfolios, comprehensive diagnostic assays, and innovative therapeutic options to secure significant market positions. Strategic moves like mergers, acquisitions, and collaborations with research institutes enhance their capabilities and extend market reach across diverse applications, including cardiology, oncology, and autoimmune conditions. Additionally, focused investment in R&D enables these companies to innovate biomarker-based solutions, addressing unmet needs in early diagnosis and personalized medicine.
 

Thrombosis and Hemostasis Biomarkers Market Companies

Major players operating in the thrombosis and hemostasis biomarkers industry are:

• Abbott Laboratories
• ARUP Laboratories
• Biomedica Diagnostics
• BioMerieux
• Cincinnati Children's Hospital Medical Center
• Cleveland Clinic Laboratories
• Diazyme Laboratories
• F. Hoffmann-La Roche
• HORIBA
• Mayo Clinic Laboratories
• QuidelOrtho
• Siemens Healthineers
• Thermo Fisher Scientific
• Werfen
   

Thrombosis and Hemostasis Biomarkers Industry News

• In June 2024, HORIBA launched the Yumizen H550 compact hematology analyzers, which combine ESR and CBC/Diff capabilities. This range aims to provide affordable, configurable hematology options, enhancing applications for small to mid-throughput laboratories in the market.
   
• In June 2024, HORIBA announced that its Yumizen H2500 high-throughput hematology analyzer received FDA 510(k) clearance. This advancement allows for the analyzer's availability in the U.S., enhancing diagnostic capabilities in the market.
   

The thrombosis and hemostasis biomarkers market research report include an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Analyzers
• Reagents & consumables

Market, By Test Location

• Clinical laboratory tests
• Point-of-care tests

Market, By Test Type

• D-dimer
• Anti-thrombin III
• Plasminogen
• Soluble fibrin
• Factor VIII
• Post-thrombin (PT)
• Activated partial thromboplastin time (APTT) test
• Other test types

Market, By Application

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Disseminated intravascular coagulation (DIC)
• Other test applications

Market, By End Use

• Hospitals and clinics
• Diagnostic laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE